Skip to main content

Table 1 Patient characteristics (by arm and overall)

From: A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML

Characteristic All Patients …in Arm A …in Arm B
Consented 25 (100%) 11 (44%) 14 (56%)
Randomized and treated 25 (100%) 11 (44%) 14 (56%)
Evaluable for all study endpoints 24 (96%) 10 (40%) 14 (56%)
Sex:
 Male 12 (48%) 7 (58%) 5 (42%)
 Female 13 (52%) 4 (31%) 9 (69%)
Age, years
 Median (range) 8.0 (1–16) 8 (2–16) 7.5 (1–16)
Race:
 White 20 (80%) 8 (32%) 12 (48%)
 African-American 1 (4%) 1 (4%) 0 (0%)
 Asian 1 (4%) 0 (0%) 1 (4%)
 American Indian or Alaska native 1 (4%) 1 (4%) 0 (0%)
 Other 2 (8%) 1 (4%) 1 (4%)
Ethnicity, Hispanic 6 (24.0)   
Ethnicity, not Hispanic or Latino 19 (76.0)   
Cytogenetic risk groups:
 Favorable 4 (8%) 1 (4%) 3 (12%)
  Intermediate 17 (68%) 6 (24%) 11 (44%)
 Unfavorable 4 (16%) 4 (16%) 0 (0%)
Cytogenetics:
 Normal 7 (28%) 3 (12%) 4 (16%)
 t(8;21) 4 (16%) 1 (4%) 3 (12%)
 11q23 9 (36%) 5 (20%) 4 (16%)
 Other 5 (20%) 2 (8%) 3 (12%)
Location:
 Alberta (Canada) 1 (4%) 1 (4%) 0 (0%)
 Children’s Hospital Central California 1 (4%) 0 (0%) 1 (4%)
 Denver 8 (32%) 5 (20%) 3 (12%)
 Emory 1 (4%) 0 (0%) 1 (4%)
 Johns Hopkins 5 (20%) 5 (20%) 0 (0%)
 John Hunter Hospital (Australia) 2 (8%) 0 (0%) 2 (8%)
 Mayo Clinic 1 (4%) 1 (4%) 0 (0%)
 Nationwide Children’s Hospital 1 (4%) 0 (0%) 1 (4%)
 Phoenix Children’s Hospital 1 (4%) 0 (0%) 1 (4%)
 Primary Children’s Hospital 1 (4%) 0 (0%) 1 (4%)
 Royal Children’s Hospital (Australia) 3 (12%) 1 (4%) 2 (8%)